Table 2. Efficacy of Evolocumab in Patients with Peripheral Artery Disease Symptomatic PAD Symptomatic PAD without prior MI or Stroke Efficacy Outcomes Placebo Evolocumab Hazard Ratio p-value Placebo Evolocumab Hazard Ratio p-value Outcome, N=1,784 N=1,858 (95% CI) N=748 N=757 (95% CI) 2.5 yr KM 2.5 yr KM rate 2.5 yr KM 2.5 yr KM rate (%) (%) rate (%) rate (%) Primary Endpoint 16.8% 13.3% 0.79 0.0098 12.6% 7.7% 0.67 0.0283 (0.66 0.94) (0.47 0.96) – – CV Death, MI, Stroke (MACE) 13.0% 9.5% 0.73 0.0040 10.3% 5.5% 0.57 0.0095 (0.59 0.91) (0.38 0.88) – – CVD 3.8% 4.0% 1.02 4.4% 2.9% 0.78 (0.71 1.48) (0.39 1.57) – – MI 7.9% 5.2% 0.69 5.7% 2.9% 0.66 (0.52 0.91) (0.38 1.14) – – Stroke 3.1% 1.8% 0.59 2.5% 0.7% 0.30 (0.38 0.92) (0.11 0.82) – – Ischemic Stroke 2.9% 1.7% 0.57 2.4% 0.5% 0.25 (0.35 0.90) (0.08 0.77) – – Coronary revascularization 9.6% 7.0% 0.79 6.9% 4.0% 0.70 (0.62 1.01) (0.44 1.13) – – All death 6.7% 6.2% 0.92 6.4% 4.9% 0.86 (0.69 1.23) (0.51 1.45) – –
Table 2. Efficacy of Evolocumab in Patients with Peripheral Artery Disease Efficacy Outcomes Symptomatic PAD Symptomatic PAD without prior MI or Stroke Outcome, Placebo N=1,784 2.5 yr KM rate (%) Evolocumab N=1,858 2.5 yr KM rate (%) Hazard Ratio (95% CI) p-value Placebo N=748 2.5 yr KM rate (%) Evolocumab N=757 2.5 yr KM rate (%) Hazard Ratio (95% CI) p-value Primary Endpoint 16.8% 13.3% 0.79 (0.66 – 0.94) 0.0098 12.6% 7.7% 0.67 (0.47 – 0.96) 0.0283 CV Death, MI, Stroke (MACE) 13.0% 9.5% 0.73 (0.59 – 0.91) 0.0040 10.3% 5.5% 0.57 (0.38 – 0.88) 0.0095 CVD 3.8% 4.0% 1.02 (0.71 – 1.48) 4.4% 2.9% 0.78 (0.39 – 1.57) MI 7.9% 5.2% 0.69 (0.52 – 0.91) 5.7% 2.9% 0.66 (0.38 – 1.14) Stroke 3.1% 1.8% 0.59 (0.38 – 0.92) 2.5% 0.7% 0.30 (0.11 – 0.82) Ischemic Stroke 2.9% 1.7% 0.57 (0.35 – 0.90) 2.4% 0.5% 0.25 (0.08 – 0.77) Coronary revascularization 9.6% 7.0% 0.79 (0.62 – 1.01) 6.9% 4.0% 0.70 (0.44 – 1.13) All death 6.7% 6.2% 0.92 (0.69 – 1.23) 6.4% 4.9% 0.86 (0.51 – 1.45)
FOURIER%2bLow%2bdensity%2blipoprotein%2bpaper%252C%2baccepted%252C%2bCirculation%2b25.10.17.docx